Brief: AB Science Says Health Canada Issued Notice Of Non-Compliance-Withdrawal For Masitinib In ALS
26/02/2024 17:38
Feb 26 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A
NOTICE OF
NON-COMPLIANCE-WITHDRAWAL (NON/W) FOR MASITINIB IN ALS
* AB SCIENCE INTENDS TO SUBMIT A REQUEST FOR RECONSIDERATION
* HEALTH CANADA STATED THAT A REQUEST FOR RECONSIDERATION
CAN BE
FILED WITHIN 30 DAYS OF RECEIVING NON/W.
* RECONSIDERATION PROCESS WILL RE-EXAMINE, WITH NEW
ASSESSORS,
DECISION BASED ON INFORMATION THAT WAS INCLUDED IN ORIGINAL
SUBMISSION
Source text for Eikon: ID:nGNXm0hyM
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease